# EpiCor PET (Fermentate derived from Saccharomyces cerevisiae)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/epicor-pet
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Saccharomyces cerevisiae fermentate, Dried yeast fermentate, Yeast postbiotic, S. cerevisiae metabolites, Fermented baker's yeast extract, Postbiotic yeast fermentate, EpiCor for pets

## Overview

EpiCor PET is a whole-food fermentate derived from Saccharomyces cerevisiae yeast, containing [beta-glucan](/ingredients/condition/immune-support)s, mannan oligosaccharides, nucleotides, and [antioxidant](/ingredients/condition/antioxidant)s that modulate gut immunity and microbiome composition. It acts primarily by strengthening intestinal tight junctions, reducing [intestinal permeability](/ingredients/condition/gut-health), and acting as a prebiotic substrate to support beneficial bacterial populations in companion animals.

## Health Benefits

• Improves digestive comfort by reducing bloating, gas, and normalizing stool frequency/consistency (demonstrated in 80-person RCT)
• Enhances gut barrier function by reducing [intestinal permeability](/ingredients/condition/gut-health) markers like zonulin and endotoxins (moderate evidence from clinical trials)
• Provides prebiotic effects by increasing beneficial bacteria like lactobacilli and bifidobacteria while reducing pathogens (supported by SHIME model studies)
• Reduces intestinal inflammation through decreased [pro-inflammatory cytokine](/ingredients/condition/inflammation)s (preliminary evidence from in vitro Caco-2/THP-1 cocultures)
• Supports mucosal defense in constipated populations (demonstrated in PMC10895063 clinical trial)

## Mechanism of Action

EpiCor PET contains beta-1,3/1,6-glucans that bind to Dectin-1 and TLR-2 receptors on intestinal epithelial and dendritic cells, modulating NFκB signaling to reduce [pro-inflammatory cytokine](/ingredients/condition/inflammation) release while supporting secretory IgA production. Its mannan oligosaccharides competitively inhibit pathogen adhesion to intestinal mucosa and serve as fermentable substrate for Lactobacillus and Bifidobacterium species, increasing short-chain fatty acid (SCFA) production including butyrate, which upregulates tight junction proteins claudin-1 and occludin. Additionally, its polyphenol and antioxidant fractions reduce [oxidative stress](/ingredients/condition/antioxidant) markers, indirectly lowering zonulin secretion and endotoxin translocation across the gut epithelium.

## Clinical Summary

An 80-person randomized controlled trial demonstrated that EpiCor fermentate significantly reduced bloating, normalized stool frequency, and improved overall digestive comfort compared to placebo over a 4-week intervention period. Clinical trials in humans and translational animal studies have shown measurable reductions in zonulin (a tight junction regulator) and circulating lipopolysaccharide (LPS) endotoxin levels, indicating improved [intestinal barrier integrity](/ingredients/condition/gut-health). Prebiotic efficacy has been confirmed through fecal microbiome analyses showing increased Bifidobacterium and Lactobacillus counts alongside elevated fecal SCFA concentrations. Evidence for the pet-specific formulation (EpiCor PET) is primarily extrapolated from human trials and in vitro fermentation studies; dedicated large-scale RCTs in dogs and cats remain limited.

## Nutritional Profile

EpiCor PET is a whole-food fermentate derived from Saccharomyces cerevisiae yeast, produced through a proprietary fermentation and drying process. Key bioactive components include: [beta-glucan](/ingredients/condition/immune-support)s (approximately 20-30% of dry weight, primarily 1,3/1,6-linked), mannoproteins and mannan-oligosaccharides (~25-35%), and a complex array of metabolites generated during fermentation. Protein content is approximately 35-45% of dry weight, comprising yeast structural proteins and peptides with moderate bioavailability due to cell wall processing. Nucleotides and nucleosides (including adenosine, uridine) are present at measurable concentrations contributing to immune signaling. B-vitamins are naturally present including B1 (thiamine), B2 (riboflavin), B3 (niacin), B6, and folate at low but biologically relevant concentrations inherent to yeast biomass. Minerals include zinc (~3-5 mg/100g), selenium (variable, strain-dependent), iron, and magnesium in organically bound forms with moderate bioavailability. Bioactive [antioxidant](/ingredients/condition/antioxidant) compounds include [glutathione](/ingredients/condition/detox), superoxide dismutase (SOD), and phenolic metabolites generated during fermentation. Short-chain fatty acid precursors and organic acids (including acetic acid, lactic acid) from fermentation are present. Dietary fiber equivalents from beta-glucans and chitin in the cell wall contribute approximately 15-25% of dry weight. Typical serving doses range from 500 mg to 1 g/day in studied formulations, with bioavailability of beta-glucans and fermentation metabolites enhanced compared to non-fermented yeast due to partial cell wall disruption during processing.

## Dosage & Preparation

Clinically studied dose is 500 mg/day as a powder in single servings, taken for 6 weeks or longer for gut comfort and barrier function support. The product is used as a non-standardized dried fermentate powder without extract forms. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

EpiCor PET is generally regarded as safe for dogs and cats, with no serious adverse events reported in available studies at recommended supplemental doses, typically ranging from 40–500 mg/day depending on animal body weight. Because it stimulates immune pathways via TLR-2 and Dectin-1 signaling, caution is theoretically warranted in pets receiving immunosuppressive medications such as cyclosporine or corticosteroids, as enhanced immune activation could partially counteract drug effects. Pets with confirmed yeast allergies (Saccharomyces cerevisiae) should be evaluated by a veterinarian before use, as the fermentate is yeast-derived, though the fermentation process substantially alters the antigenic profile. No reproductive or developmental toxicity data are available for pregnant or lactating animals, so use in these populations should be guided by veterinary judgment.

## Scientific Research

Key clinical evidence includes a randomized, double-blind, placebo-controlled trial (NCT03051399) with 80 adults showing improvements in digestive comfort and [gut barrier](/ingredients/condition/gut-health) function at 500mg/day for 6 weeks. Additional RCTs (PMC5584023, PMC10895063) demonstrated reduced GI symptoms and improved bowel movements in adults with digestive discomfort.

## Historical & Cultural Context

No historical or traditional medicinal use has been identified for EpiCor. It is a modern branded postbiotic developed through commercial fermentation technology, lacking roots in traditional medicine systems like Ayurveda, TCM, or folk medicine.

## Synergistic Combinations

Probiotics, Prebiotics, L-Glutamine, [Digestive Enzyme](/ingredients/condition/gut-health)s, Zinc Carnosine

## Frequently Asked Questions

### What is EpiCor PET and how is it made?

EpiCor PET is a dried whole-food fermentate produced by culturing Saccharomyces cerevisiae yeast under specific nutrient and temperature conditions, then heat-inactivating and drying the entire fermentation culture. The resulting ingredient retains a complex matrix of beta-glucans, mannan oligosaccharides, nucleotides, amino acids, vitamins, and polyphenolic antioxidants. This multi-component profile distinguishes it from isolated beta-glucan or probiotic supplements.

### How does EpiCor PET improve gut health in dogs and cats?

EpiCor PET improves gut health through two complementary mechanisms: it acts as a prebiotic, selectively feeding Lactobacillus and Bifidobacterium species which produce butyrate and other SCFAs that nourish colonocytes, and it strengthens intestinal tight junctions by reducing zonulin secretion and endotoxin translocation. Its beta-1,3/1,6-glucans also bind pattern recognition receptors on gut immune cells, promoting balanced mucosal immune responses including elevated secretory IgA. These combined actions reduce symptoms like gas, loose stools, and intestinal discomfort.

### What is the recommended dosage of EpiCor PET for dogs?

Manufacturer guidelines for EpiCor PET in dogs typically suggest approximately 40–250 mg per day for small to medium breeds and up to 500 mg per day for large breeds, though exact dosing varies by product formulation and the animal's health status. Published human studies used 500 mg/day of the human-grade EpiCor as a benchmark dose, and pet formulations are generally scaled by body weight. Always consult a veterinarian to determine the appropriate dose for your specific pet's size, age, and health condition.

### Can EpiCor PET be given to cats as well as dogs?

EpiCor PET is formulated for companion animals including both dogs and cats, though most published efficacy and safety data originate from human trials or canine-focused studies. Cats have distinct gastrointestinal physiology, including a shorter intestinal transit time and obligate carnivore microbiome composition, which may influence prebiotic fermentation outcomes. Veterinary guidance is recommended when supplementing cats, particularly those with inflammatory bowel disease or on concurrent medications.

### Is EpiCor PET safe for pets with yeast sensitivities?

EpiCor PET is derived from Saccharomyces cerevisiae, so pets with documented hypersensitivity to Saccharomyces yeast should be assessed by a veterinarian before supplementation. The heat-inactivation and fermentation processing significantly alter the protein and carbohydrate structures of the yeast, reducing but not eliminating potential allergenicity compared to live or raw yeast. No clinical reports of allergic reactions to EpiCor in pets have been widely published, but individual sensitivity remains theoretically possible, and a supervised introduction at low doses is prudent for sensitive animals.

### What clinical evidence supports EpiCor PET's effectiveness for digestive health in pets?

EpiCor PET demonstrated measurable improvements in an 80-person clinical trial, showing reduced bloating, gas, and normalized stool frequency and consistency. Additionally, clinical studies have documented its ability to reduce intestinal permeability markers such as zonulin and endotoxins, indicating enhanced gut barrier function. The ingredient has moderate-level evidence from multiple clinical trials supporting its prebiotic effects and capacity to increase beneficial bacteria populations.

### Which pets benefit most from EpiCor PET supplementation?

EpiCor PET is most beneficial for pets experiencing digestive discomfort, including those with irregular stools, excessive gas, or bloating. Pets with compromised gut barrier function or dysbiosis (imbalanced gut bacteria) may particularly benefit from its prebiotic properties and ability to promote lactobacilli and bifidobacteria growth. It is suitable for both dogs and cats, making it a versatile option for multi-pet households.

### How does EpiCor PET compare to other pet probiotic and prebiotic ingredients?

Unlike traditional probiotics that introduce live bacteria, EpiCor PET is a fermentate that works as a prebiotic to selectively feed beneficial bacteria already present in the gut. This makes it distinct from live probiotic strains and allows it to work synergistically with other digestive support ingredients. EpiCor PET's yeast-derived fermentate provides additional immune and digestive benefits beyond simple bacterial supplementation, offering a more comprehensive approach to gut health.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*